Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 1/20 | 0.41 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6062401 | 0.85 | L3MBTL1 (0.40) | SLC1A3SLC1A1LMNASMN1; SMN2L3MBTL1 | |
| SCHEMBL7043168 | 0.82 | MAPK1 (0.48) | SLC1A3SLC1A1LMNASMN1; SMN2L3MBTL1 | |
| SCHEMBL6465943 | 0.81 | ANPEP (0.44) | SLC1A3SLC1A1LMNASMN1; SMN2L3MBTL1 | |
| SCHEMBL6063445 | 0.79 | PTGER4 (0.47) | SLC1A3SLC1A1LMNASMN1; SMN2L3MBTL1 | |
| SCHEMBL7799710 | 0.79 | SLC1A3 (0.42) | SLC1A3SLC1A1LMNASMN1; SMN2L3MBTL1 | |
| SCHEMBL7046317 | 0.79 | SLC1A3 (0.39) | SLC1A3SLC1A1LMNASMN1; SMN2L3MBTL1 | |
| SCHEMBL7043362 | 0.79 | KCNA5 (0.39) | SLC1A3SLC1A1LMNASMN1; SMN2L3MBTL1 | |
| SCHEMBL7046968 | 0.79 | ELANE (0.44) | SLC1A3SLC1A1LMNASMN1; SMN2L3MBTL1 | |
| SCHEMBL7790161 | 0.77 | LMNA (0.46) | SLC1A3SLC1A1LMNASMN1; SMN2L3MBTL1 | |
| SCHEMBL7046899 | 0.77 | CYP3A4 (0.39) | SLC1A3SLC1A1LMNASMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2003-12-18 | — | — | US | disclosed |
| US-6576630-B1 | Alkanoyl substituted benzooxazoles or naphthooxazoles | AXYS PHARMACEUTICALS, INC. | 2003-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | SERPINB1, CTRL, CTSZ | SLC1A3 4389/4885SLC1A1 4414/4885LMNA 1755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.